362 related articles for article (PubMed ID: 21644034)
1. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer.
Ladoire S; Martin F; Ghiringhelli F
Cancer Immunol Immunother; 2011 Jul; 60(7):909-18. PubMed ID: 21644034
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.
Salama P; Phillips M; Grieu F; Morris M; Zeps N; Joseph D; Platell C; Iacopetta B
J Clin Oncol; 2009 Jan; 27(2):186-92. PubMed ID: 19064967
[TBL] [Abstract][Full Text] [Related]
3. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer.
Suzuki H; Chikazawa N; Tasaka T; Wada J; Yamasaki A; Kitaura Y; Sozaki M; Tanaka M; Onishi H; Morisaki T; Katano M
Cancer Immunol Immunother; 2010 May; 59(5):653-61. PubMed ID: 19908042
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers.
Badoual C; Hans S; Rodriguez J; Peyrard S; Klein C; Agueznay Nel H; Mosseri V; Laccourreye O; Bruneval P; Fridman WH; Brasnu DF; Tartour E
Clin Cancer Res; 2006 Jan; 12(2):465-72. PubMed ID: 16428488
[TBL] [Abstract][Full Text] [Related]
6. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.
Ladoire S; Arnould L; Apetoh L; Coudert B; Martin F; Chauffert B; Fumoleau P; Ghiringhelli F
Clin Cancer Res; 2008 Apr; 14(8):2413-20. PubMed ID: 18413832
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer.
Tosolini M; Kirilovsky A; Mlecnik B; Fredriksen T; Mauger S; Bindea G; Berger A; Bruneval P; Fridman WH; Pagès F; Galon J
Cancer Res; 2011 Feb; 71(4):1263-71. PubMed ID: 21303976
[TBL] [Abstract][Full Text] [Related]
8. The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer.
Giatromanolaki A; Bates GJ; Koukourakis MI; Sivridis E; Gatter KC; Harris AL; Banham AH
Gynecol Oncol; 2008 Aug; 110(2):216-21. PubMed ID: 18533240
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells.
Leveque L; Deknuydt F; Bioley G; Old LJ; Matsuzaki J; Odunsi K; Ayyoub M; Valmori D
J Immunother; 2009; 32(2):101-8. PubMed ID: 19238008
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer.
Mahmoud SM; Paish EC; Powe DG; Macmillan RD; Lee AH; Ellis IO; Green AR
Breast Cancer Res Treat; 2011 May; 127(1):99-108. PubMed ID: 20556505
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients.
Deng L; Zhang H; Luan Y; Zhang J; Xing Q; Dong S; Wu X; Liu M; Wang S
Clin Cancer Res; 2010 Aug; 16(16):4105-12. PubMed ID: 20682706
[TBL] [Abstract][Full Text] [Related]
12. Potential role of plasmacytoid dendritic cells for FOXP3+ regulatory T cell development in human colorectal cancer and tumor draining lymph node.
Gai XD; Song Y; Li C; Lei YM; Yang B
Pathol Res Pract; 2013 Dec; 209(12):774-8. PubMed ID: 24080284
[TBL] [Abstract][Full Text] [Related]
13. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer.
Aruga T; Suzuki E; Saji S; Horiguchi S; Horiguchi K; Sekine S; Kitagawa D; Funata N; Toi M; Sugihara K; Kuroi K
Oncol Rep; 2009 Aug; 22(2):273-8. PubMed ID: 19578766
[TBL] [Abstract][Full Text] [Related]
14. Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer.
Xu L; Xu W; Qiu S; Xiong S
Clin Immunol; 2010 Jun; 135(3):466-75. PubMed ID: 20181533
[TBL] [Abstract][Full Text] [Related]
15. Foxp3+IL-17+ T cells promote development of cancer-initiating cells in colorectal cancer.
Yang S; Wang B; Guan C; Wu B; Cai C; Wang M; Zhang B; Liu T; Yang P
J Leukoc Biol; 2011 Jan; 89(1):85-91. PubMed ID: 20952660
[TBL] [Abstract][Full Text] [Related]
16. T cell subsets and colorectal cancer: discerning the good from the bad.
Scurr M; Gallimore A; Godkin A
Cell Immunol; 2012 Sep; 279(1):21-4. PubMed ID: 23041206
[TBL] [Abstract][Full Text] [Related]
17. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma.
Liotta F; Gacci M; Frosali F; Querci V; Vittori G; Lapini A; Santarlasci V; Serni S; Cosmi L; Maggi L; Angeli R; Mazzinghi B; Romagnani P; Maggi E; Carini M; Romagnani S; Annunziato F
BJU Int; 2011 May; 107(9):1500-6. PubMed ID: 20735382
[TBL] [Abstract][Full Text] [Related]
18. Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients.
Yang ZQ; Yang ZY; Zhang LD; Ping-Bie ; Wang SG; Ma KS; Li XW; Dong JH
Hum Immunol; 2010 Dec; 71(12):1180-6. PubMed ID: 20870003
[TBL] [Abstract][Full Text] [Related]
19. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.
Heimberger AB; Abou-Ghazal M; Reina-Ortiz C; Yang DS; Sun W; Qiao W; Hiraoka N; Fuller GN
Clin Cancer Res; 2008 Aug; 14(16):5166-72. PubMed ID: 18698034
[TBL] [Abstract][Full Text] [Related]
20. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
Miracco C; Mourmouras V; Biagioli M; Rubegni P; Mannucci S; Monciatti I; Cosci E; Tosi P; Luzi P
Oncol Rep; 2007 Nov; 18(5):1115-22. PubMed ID: 17914561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
